Affiliation:
1. Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
2. Department of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA
3. Mayo Clinic, Scottsdale, Arizona, USA
Abstract
Abstract
Trial Information
Click here to access other published clinical trials.
Lessons Learned
Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors. FTD/TPI has an acceptable safety profile and should be studied further in patients with advanced biliary tract carcinoma after progression on standard first-line therapy.
Background
Patients with advanced biliary tract carcinoma (BTC) refractory to first-line therapy lack an established second-line option. Trifluridine/tipiracil (FTD/TPI) has activity in both fluoropyrimidine-sensitive and -resistant tumors, which led us to conduct a single arm phase II trial to evaluate the safety and efficacy of FTD/TPI for patients previously treated for advanced BTC.
Methods
Patients with advanced BTC previously treated with at least one line of chemotherapy were enrolled and treated with FTD/TPI until disease progression or unacceptable toxicity. The primary endpoint target was to have at least 6 patients who were progression free and alive at 16 weeks among 25 evaluable patients. Secondary endpoints included overall survival (OS), overall response rate (ORR), progression-free survival (PFS), and toxicity.
Results
Of 27 evaluable patients, 59.3% received at least three prior lines of therapy, and 81.5% had previous exposure to fluoropyrimidine. Eight (32%, 95% confidence interval [CI], 14.9%–53.5%) patients were progression free at 16 weeks in the primary analysis population (n = 25), which met the predefined efficacy criteria. Median PFS and OS were 3.8 (95% CI, 2–5.8 months) and 6.1 (95% CI, 4.4–11.4 months) months, respectively. No objective responses were seen. There were no unexpected safety signals noted.
Conclusion
FTD/TPI demonstrated promising antitumor activity, with acceptable toxicity, in heavily pretreated patients with advanced BTC.
Publisher
Oxford University Press (OUP)
Reference29 articles.
1. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010
2. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study;Walter;Eur J Cancer,2013
3. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells;Emura;Int J Mol Med,2004
4. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA;Emura;Int J Oncol,2004
5. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors;Hong;Cancer,2006
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献